Key Highlights

  • Regeneron (NASDAQ:REGN) rose about 12 percent on October 30, 2026 after third quarter Revenue climbed 36 percent to USD 5.1 billion, against about USD 4.56 billion expected, based on the company release and published market data.
  • Adjusted Earnings were USD 20.07 per share, up 70 percent and well above the USD 16.25 consensus, on a day when the Nasdaq Composite fell about 2.9 percent.
  • Dupixent global sales reached USD 6.5 billion, up 35 percent, and collaboration revenue from Sanofi (NASDAQ:SNY) rose USD 1.1 billion to USD 2.72 billion, about four fifths of the revenue gain.
  • Original Eylea US sales fell 41 percent to USD 400 million, while combined US Eylea sales including Eylea HD slipped 1 percent, which shows the drug is being replaced and not simply lost.

A Beat Led by Dupixent

Regeneron (NASDAQ:REGN) reported before the open on October 30, 2026 and its shares rose about 12 percent, with published accounts ranging from 11.5 to 13.3 percent depending on timing, on a day when the Nasdaq Composite fell about 2.9 percent. Revenue of USD 5.1 billion was up 36 percent. Dupixent, which Regeneron develops with Sanofi, generated USD 6.5 billion of global sales, adding about USD 1.7 billion year over year. Regeneron books a share of the profit as collaboration revenue, which rose USD 1.1 billion to USD 2.72 billion. Ebglyss, the Eli Lilly (NYSE:LLY) eczema drug on which Regeneron earns a royalty, contributed USD 202 million in the quarter.

Eylea Under Pressure

The less comfortable part of the report is Eylea, the eye drug that was once Regeneron's largest product. Original Eylea US sales fell 41 percent to USD 400 million as competition and Biosimilars arrived over the past year, including Pavblu from Amgen (NASDAQ:AMGN), which reported USD 287 million of second quarter sales. Combined US sales of Eylea and its higher-dose version Eylea HD slipped 1 percent, so the Franchise is roughly stable only because patients are shifting formulations. Separately, Sanofi agreed to pay USD 1.0 billion upfront for four new antibodies, which Regeneron will book in the fourth quarter and which supports the pipeline but depends on trial results.

Risks and What to Watch

Dupixent growth drives the story, so any slowdown, new competition in immunology or pricing pressure would hit earnings quickly. Eylea could erode further as biosimilars gain share. A 12 percent one-day gain also raises expectations for the next report, and Regeneron (NASDAQ:REGN) trades near its highest level in about two years, according to published commentary. Sector moves matter too, as does the wider market: biotech held up on October 30 while technology fell, but a rotation back could reverse that. Detailed Libtayo, cash and buyback figures were not retrieved here, so readers should check the 8-K filing for those items. Regeneron (NASDAQ:REGN) next reports in early 2027.

Where Things Stand

A biotech jumped about 12 percent because its revenue growth, led by Dupixent, was much stronger than expected. Regeneron (NASDAQ:REGN) beat on both revenue and adjusted earnings, and a USD 1.0 billion upfront payment from Sanofi adds to the pipeline story. The balance of evidence is positive, with Eylea erosion the main drag and no guarantee that Dupixent keeps growing at this pace. The next checks are Dupixent growth, Eylea share and any new Sanofi or Lilly milestones.